Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors from the central anxious system, conolidine modulates alternate molecular targets. A Science Developments research found that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://erichd936ygn9.wikiap.com/user